Trial Profile
Pharmacokinetics of Enzastaurin HCl in Native Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 15 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.